Roivant Sciences Ltd. (ROIV)
35.72
+0.22
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
35.68
-0.04
(-0.11%)
After-Hours: 20:00
Roivant Sciences Enterprise Value : 22.77B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 22.77B |
| October 01, 2026 | 22.61B |
| September 30, 2026 | 23.38B |
| September 29, 2026 | 23.33B |
| September 28, 2026 | 23.68B |
| September 25, 2026 | 22.82B |
| September 24, 2026 | 23.06B |
| September 23, 2026 | 23.56B |
| September 22, 2026 | 24.57B |
| September 21, 2026 | 25.13B |
| September 18, 2026 | 25.69B |
| September 17, 2026 | 25.84B |
| September 16, 2026 | 25.55B |
| September 15, 2026 | 25.50B |
| September 14, 2026 | 26.60B |
| September 11, 2026 | 26.45B |
| September 10, 2026 | 26.54B |
| September 09, 2026 | 27.17B |
| September 08, 2026 | 26.93B |
| September 04, 2026 | 22.19B |
| September 03, 2026 | 21.82B |
| September 02, 2026 | 21.65B |
| September 01, 2026 | 21.90B |
| August 31, 2026 | 21.98B |
| August 28, 2026 | 22.04B |
| Date | Value |
|---|---|
| August 27, 2026 | 24.11B |
| August 26, 2026 | 23.51B |
| August 25, 2026 | 23.31B |
| August 24, 2026 | 23.23B |
| August 21, 2026 | 23.18B |
| August 20, 2026 | 23.57B |
| August 19, 2026 | 23.98B |
| August 18, 2026 | 23.96B |
| August 17, 2026 | 23.14B |
| August 14, 2026 | 23.11B |
| August 13, 2026 | 23.17B |
| August 12, 2026 | 23.08B |
| August 11, 2026 | 22.43B |
| August 10, 2026 | 22.81B |
| August 07, 2026 | 23.21B |
| August 06, 2026 | 22.33B |
| August 05, 2026 | 21.96B |
| August 04, 2026 | 21.95B |
| August 03, 2026 | 21.03B |
| July 31, 2026 | 21.46B |
| July 30, 2026 | 21.90B |
| July 29, 2026 | 20.71B |
| July 28, 2026 | 21.41B |
| July 27, 2026 | 22.04B |
| July 24, 2026 | 22.25B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oxford Biomedica Plc | -- |
| Bicycle Therapeutics Plc | -324.57M |
| Arbutus Biopharma Corp. | 790.47M |
| Adaptimmune Therapeutics Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 5.393B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -290.61M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 191.28M |
| EPS Diluted (Quarterly) | -0.2634 |
| Gross Profit Margin (Quarterly) | 38.70% |
| Profit Margin (Quarterly) | -20.15K% |
| Earnings Yield | -1.23% |
| Normalized Earnings Yield | -3.426 |